Navigation Links
Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management

PHILADELPHIA, Jan. 15 /PRNewswire/ -- Premier Research Group plc (AIM: PRG), the international pharmaceutical services group, announces the appointment of Patrick Melvin as Senior Director, Clinical Trial Management specializing in oncology-related research. In this position, Mr. Melvin will play a leading role in the operations, strategic planning and corporate development of Premier Research's growing portfolio of oncology business.

Over the past nine years, Mr. Melvin managed hematology/oncology programs ranging from Phase I first-in-man studies through pivotal global Phase III programs. His early phase experience included multiple variations of early phase designs, including PK/PD studies, traditional dose-escalating maximum tolerated dose studies, Simon two-stage studies, and adaptive design studies. The later phase studies included extensive global experience in hematology/oncology clinical research including clinical program and client activities in the United States, Western and Eastern Europe, Latin America, and Asia. His responsibilities incorporated consulting with clients on clinical development plans and protocol design for new hematology/oncology studies. Mr. Melvin began his clinical research career as a CRA at a global clinical research organization and, after five years of serving in various monitoring positions, entered project management specializing in hematology and oncology drug development.

"Mr. Melvin is an exceptional addition to our team," said Krista Armstrong, Ph.D., Vice President, Clinical Trial Management. "As we continue to expand our presence within the oncology market, Mr. Melvin's substantial clinical and management expertise will be beneficial in continuing to establish Premier Research as an industry leader."

About Premier Research

Premier Research is a leading solutions-driven CRO leveraging their commitment to therapeutic focus and scientific expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for Analgesia, CNS, Infectious Disease, and Oncology and have a wealth of experience in medical device and pediatric research. Premier Research has 29 offices and operates in more than 30 countries across Europe and North America. They employ a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific and medical experts, and staff at a well-established network of dedicated clinical sites.

SOURCE Premier Research Group plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
2. Premier Research Appoints Global Head of Human Resources
3. Premier Research Appoints Melissa Jones as Vice President, International Business Development
4. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
5. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
6. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
7. Association of Clinical Research Organizations (ACRO) Elects New Officers for 2008
8. Biomoda Hires Senior Scientist to Expand Research & Development Effort
9. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
10. SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations
11. Researchers use magnetism to target cells to animal arteries
Post Your Comments:
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
Breaking Biology Technology:
(Date:10/26/2015)... ALTO, Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern ... Alliance , today announced the launch of its latest ... first unified platform enabling organizations to use standards-based authentication ... The Nok Nok S3 Authentication Suite is ideal for ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
(Date:10/22/2015)... AWRE ), a leading supplier of biometrics software and services, ... 2015.  --> --> Revenue ... of 33% compared to $6.0 million in the same quarter last ... million, or $0.10 per diluted share, which compared to $2.6 million, ... ago.  --> --> Lower ...
Breaking Biology News(10 mins):